Johnson & Johnson vs Trade Desk Inc — how do they compare? Johnson & Johnson trades at $260.76 (market cap $626.09B), while Trade Desk Inc trades at $13.46 (market cap $6.37B). The key difference: Johnson & Johnson is far larger — about 98.3× Trade Desk Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| JNJ | TTD | |
|---|---|---|
Market Cap | $626.09B | $6.37B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $55.36 |
52-Week Low | $172.78 | $13.39 |
Enterprise Value | $654.37B | $5.32B |
Dividend Yield | 2.06% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
The Trade Desk (TTD) stock trades at $13.33, near its 52-week low, reflecting a bearish technical trend with recent earnings misses and a 12% revenue decline guidance for Q3 2026. Despite strong profitability margins, the company faces execution gaps and competitive pressures in the ad-tech sector, leading to significant analyst downgrades and negative media sentiment.
Outlook remains cautious with high risk; potential exists if operational improvements reverse recent declines, but near-term headwinds from weak guidance and macroeconomic pressures suggest continued volatility. The stock's valuation appears reasonable, but investor confidence hinges on a demonstrated turnaround in revenue growth and execution stability.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →